Yesterday, 03:28 PM
Ridiculous IP rights for corporations on life-saving devices.
Corrupt FDA approval process.
Lack of competition in insurance market combined with forced insurance purchasing allowing companies like Mylan to milk the taxpayer.
...all leads to sore consumer buttholes.
That said, they "sort of" have a point. Deals with insurance companies force them to sell to insurance companies typically at a lower price. So they're really saying, I'm guessing, that we're only raising it significantly for out of network and insurance-less buyers. Not exactly a defense, but does highlight that it isn't an across-the-board increase.
The whole system of IP, marketing, investment, insurance, government approval involvement, etc. of pharmaceuticals is corrupt from the ground up. I used to work for pharma research company. Very depressing.